MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics Target Price

Where could MLTX trade next? Consensus target price: $45.

Get informed when a big investor buys or sells

+ Follow

Share Price

$16.5

Average Target Price

$45.00

172.7% upside

1 analysts in the last 4 months

High: $45 | Low: $45

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-05-11	H.C. Wainwright	$45	172.7% upside
2026-02-24	Oppenheimer	$35	112.1% upside
2026-01-14	Goldman Sachs	$10	39.4% downside
2026-01-09	H.C. Wainwright	$32	93.9% upside
2026-01-09	UBS	$24	45.5% upside
2026-01-08	UBS	$45	172.7% upside
2025-11-21	H.C. Wainwright	$26	57.6% upside
2025-11-06	Oppenheimer	$30	81.8% upside
2025-11-03	H.C. WainwrightRaghuram Selvaraju	$30	81.8% upside
2025-10-07	Oppenheimer	$25	51.5% upside
2025-09-30	Goldman Sachs	$7	57.6% downside
2025-09-30	NeedhamSerge Belanger	$20	21.2% upside
2025-09-30	Guggenheim	$20	21.2% upside
2025-09-29	Jefferies	$8	51.5% downside
2025-09-29	RBC Capital	$10	39.4% downside
2025-03-18	RBC Capital	$67	306.1% upside
2024-07-01	H.C. WainwrightRaghuram Selvaraju	$100	506.1% upside
2024-04-02	Goldman SachsRichard Law	$62	275.8% upside
2023-08-31	NeedhamSerge Belanger	$76	360.6% upside

MoonLake Immunotherapeutics (MLTX) FAQ

MoonLake Immunotherapeutics's target price stands at $45. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $45 for MLTX implies 172.7% upside versus today's price ($16.5). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how MoonLake Immunotherapeutics's target price evolved across reporting periods, while the comparison chart places MLTX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.